Managing Advanced Prostate Cancer in a Virtual Urology Clinic


Managing Advanced Prostate Cancer in a Virtual Urology Clinic

Topic: Urology
Relevant Terms: Prostate cancer; oral therapy; infusion therapy; urology practice
Primary Audience: Urologists, advanced practice nurses, and others working in urology clinics
Launch Date: 07-Sep-17
Credits: AMA PRA Category 1 Credit
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: Teaching through a Window: Optimal Management of Advanced Prostate Cancer in a Urology Practice

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Review current practices and treatment options for advanced prostate cancer
  2. Apply current guideline recommendations for chemotherapy, immunotherapy, bone-targeted therapy, and androgen suppression therapy in patients with advanced prostate cancer
  3. Recognize the quality of life issues affecting patients with advanced prostate cancer
  4. Outline the role of the urologist in the development of advanced prostate cancer centers of excellence


    Neal Shore, MD, FACS
    Director, CPI
    Carolina Urologic Research Center
    Myrtle Beach, South Carolina
    David M. Albala, MD
    Medical Director, Co-Director of Research
    Associated Medical Professionals
    Syracuse, NY
    Mark Garzotto, MD - External Reviewer
    Associate Professor of Urology and Radiation Oncology
    Oregon Health & Science University
    Director, Urologic Oncology
    Portland VAMC
    Portland, OR
    This activity was launched on September 7, 2017 and will expire on September 7, 2018.
    This activity has been designed to meet the educational needs of urologists, nurse practitioners (NPs), and physician assistants (PAs) who practice in a urologic setting. 

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

    Horizon CME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
    By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA category 1 credits™. Statement of credit will be available to print from your user history page.
    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the post-test and activity evaluation.
    • Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with an 75% or higher on the post-test to receive credit for this activity.
    • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

    Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.
    Name of Faculty Reported Financial Relationship
    Neal Shore, MD, FACS
    Dr Shore has served on a Speakers Bureau and has received funds for contracted research from Bayer, Astellas, Janssen, and Sanofi.  He has also served on an Advisory Board and has received funds for contracted research from AbbVie, Amgen, Astellas, Bayer,Ferring, Janssen, Pfizer, Sanofi, and Tolmar.
    David M. Albala, MD Dr. Albala has served on a Speakers Bureau for Genomic Health and Myriad. He has also served on an Advisory Board and has received funds for contracted research from Cellanyx Diagnostics.
    Mark Garzotto, MD Dr. Garzotto has received funds for contracted research from Merck, Astellas/Pfizer, Dendreon, and Genomic Health.
    OTHER CONTRIBUTORS  Non-faculty contributors and others involved in the planning, development, and editing/review of the content disclosed no relevant financial relationships with any ACCME defined commercial interest.
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
    This activity is supported by an educational grant from Sanofi Genzyme.      
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Supported Browsers:
    Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 6+ for Mac OSX 10.7 and above

    For video playback, install the latest version of Flash or Quicktime.
    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above

    Copyright © 2017 MedReviews, LLC. All rights reserved